Cencora, Inc. (COR) Stock Analysis and Metrics

Cencora

NYSE: COR

$312.49 ▲ +2.60 (+0.84%)

At close: Jul 27, 2026 · 11:18 AM UTC

Financial Ratios

Market Cap60.83 Bn

P/E23.83

P/S0.19

Div. Yield0.01

ROIC (Qtr)0.02

Total Debt (Qtr)12.39 Bn

Revenue Growth (1y) (Qtr)3.85

Add ratio to table…

About

Cencora is a global pharmaceutical services company that distributes prescription and over the counter medications and provides specialty logistics animal health and consulting solutions to the healthcare industry. The firm operates primarily in the pharmaceutical distribution sector delivering products from manufacturers to dispensers while also offering value added services such as specialty drug handling temperature controlled transportation and data analytics. Its core activities include wholesale drug distribution specialty pharmacy support and ancillary health care services that help manufacturers providers and patients access therapies efficiently.

Cencora generates revenue mainly through the sale of pharmaceutical products distributed to customers such as hospitals health systems physician practices and retail pharmacies. In addition the company earns fees for specialty logistics services including cold chain transport customs clearance and inventory management for biopharmaceuticals. Animal health products and veterinary supplies contribute revenue through its MWI Animal Health business while consulting services provide advisory revenue to pharmaceutical and healthcare clients. Overall revenue is driven by product sales and service fees across its diversified portfolio.

The company operates through the following segments: U. S. Healthcare Solutions International Healthcare Solutions and Other.

• U. S. Healthcare Solutions: This segment distributes pharmaceuticals and provides specialty services within the United States including delivery of brand generic and specialty drugs to health systems physician practices and pharmacies as well as solutions for oncology and other therapeutic areas.

• International Healthcare Solutions: This segment encompasses the company’s operations outside the United States comprising European distribution through Alliance Healthcare global specialty logistics via World Courier and specialty services from Innomar and PharmaLex that support multinational manufacturers and providers.

• Other: This segment includes businesses for which the company is evaluating strategic alternatives such as MWI Animal Health Profarma U. S. Consulting Services and remaining components of PharmaLex which are not considered core to the long term growth strategy.

Cencora holds a leading position among pharmaceutical distributors in North America and ranks among the top three globally alongside McKesson and Cardinal Health. Its competitive advantages stem from an extensive distribution network integrated specialty capabilities and strong relationships with manufacturers and providers which enable it to offer end to end solutions that smaller competitors cannot match.

The company serves a broad customer base that includes hospitals health systems physician practices retail pharmacies long term care facilities and animal health providers. It also works with group purchasing organizations and pharmaceutical manufacturers that rely on its logistics and distribution capabilities to bring products to market.

Investment Thesis

▲ Bull case

Cencora is strategically positioned to benefit from the accelerating adoption of specialty pharmaceuticals, particularly in high-growth areas such as cell and gene therapies, where its global specialty logistics business has delivered two consecutive quarters of operating income growth and is winning new contracts in complex therapeutic areas. This positions the company to capitalize on the industry shift toward personalized medicine, which requires sophisticated distribution capabilities that Cencora has invested in over years, creating a durable competitive advantage that is not fully reflected in current revenue growth guidance. The company’s ability to support these therapies through its CGT service line and its infrastructure for handling temperature-sensitive, high-value products provides a structural tailwind that will drive margin expansion and volume growth in the back half of fiscal 2026 and beyond, even as traditional drug distribution faces pricing pressures.
Cencora’s portfolio optimization, including the pending merger of MWI Animal Health with Covetrus and the divestiture of U.S. hub consulting services, is sharpening its focus on core pharmaceutical-centric operations, particularly its high-margin MSO platform. The integration of OneOncology and RCA is already yielding synergies through shared best practices in clinical trials, back-office operations, and physician recruitment, with management noting early progress in building shared capabilities that will accelerate growth across the MSO platform. These MSOs are not only contributors to specialty growth but are becoming increasingly valuable as health systems and physician practices seek end-to-end support for managing complex specialty drug regimens, creating a sticky, recurring revenue stream that is less vulnerable to generic conversion pressures and more aligned with long-term healthcare trends.
Despite transitory headwinds from weather, COVID-19 vaccine demand normalization, and the lappable loss of an oncology customer, Cencora’s core U.S. Healthcare Solutions operating income growth, excluding OneOncology and the lost oncology customer, was approximately 7% in Q2 FY26—inline with its long-term guidance range of 7% to 10% organic operating income growth. This underlying resilience, combined with the impending lap of the oncology customer loss in Q3 FY26 and the ramp-up of OneOncology accretion, sets the stage for a meaningful acceleration in operating income growth in the second half of the fiscal year, supporting the company’s raised EPS guidance of $17.65–$17.90 and its confidence in achieving 12% to 14% operating income growth for the full year.
Cencora’s resumption of opportunistic share repurchases, with a target of $1 billion by calendar year-end and a new $2 billion authorization, signals strong management confidence in intrinsic value and provides a tangible catalyst for EPS accretion. Combined with the company’s ongoing debt paydown—$500 million already paid down this fiscal year with a target of $1.3 billion—and the benefit of MWI being classified as an asset held for sale (suspending depreciation), these capital deployment actions are enhancing free cash flow conversion and shareholder returns, which the market may be underestimating given the current focus on transient revenue pressures.
Cencora’s appointment of Eva Boratto as CFO, with her extensive experience at CVS Health and Bath & Body Works in driving financial discipline, cost savings, and digital transformation, brings a proven track record of operational efficiency and capital allocation expertise. Her background in leading complex global finance organizations and her roles on the audit committees of Mars and UPS suggest she will strengthen financial controls, optimize working capital, and accelerate initiatives that enhance margin stability—particularly valuable as the company navigates IRA-driven price reductions and GLP-1 growth normalization. This leadership transition is a quiet but significant catalyst for sustained financial performance that is not yet priced into the stock.

Cencora is strategically positioned to benefit from the accelerating adoption of specialty pharmaceuticals, particularly in high-growth areas such as cell and gene therapies, where its global specialty logistics business has delivered two consecutive quarters of operating income growth and is winning new contracts in complex therapeutic areas. This positions the company to capitalize on the industry shift toward personalized medicine, which requires sophisticated distribution capabilities that Cencora has invested in over years, creating a durable competitive advantage that is not fully reflected in current revenue growth guidance. The company’s ability to support these therapies through its CGT service line and its infrastructure for handling temperature-sensitive, high-value products provides a structural tailwind that will drive margin expansion and volume growth in the back half of fiscal 2026 and beyond, even as traditional drug distribution faces pricing pressures.
Cencora’s portfolio optimization, including the pending merger of MWI Animal Health with Covetrus and the divestiture of U.S. hub consulting services, is sharpening its focus on core pharmaceutical-centric operations, particularly its high-margin MSO platform. The integration of OneOncology and RCA is already yielding synergies through shared best practices in clinical trials, back-office operations, and physician recruitment, with management noting early progress in building shared capabilities that will accelerate growth across the MSO platform. These MSOs are not only contributors to specialty growth but are becoming increasingly valuable as health systems and physician practices seek end-to-end support for managing complex specialty drug regimens, creating a sticky, recurring revenue stream that is less vulnerable to generic conversion pressures and more aligned with long-term healthcare trends.
Despite transitory headwinds from weather, COVID-19 vaccine demand normalization, and the lappable loss of an oncology customer, Cencora’s core U.S. Healthcare Solutions operating income growth, excluding OneOncology and the lost oncology customer, was approximately 7% in Q2 FY26—inline with its long-term guidance range of 7% to 10% organic operating income growth. This underlying resilience, combined with the impending lap of the oncology customer loss in Q3 FY26 and the ramp-up of OneOncology accretion, sets the stage for a meaningful acceleration in operating income growth in the second half of the fiscal year, supporting the company’s raised EPS guidance of $17.65–$17.90 and its confidence in achieving 12% to 14% operating income growth for the full year.
Cencora’s resumption of opportunistic share repurchases, with a target of $1 billion by calendar year-end and a new $2 billion authorization, signals strong management confidence in intrinsic value and provides a tangible catalyst for EPS accretion. Combined with the company’s ongoing debt paydown—$500 million already paid down this fiscal year with a target of $1.3 billion—and the benefit of MWI being classified as an asset held for sale (suspending depreciation), these capital deployment actions are enhancing free cash flow conversion and shareholder returns, which the market may be underestimating given the current focus on transient revenue pressures.
Cencora’s appointment of Eva Boratto as CFO, with her extensive experience at CVS Health and Bath & Body Works in driving financial discipline, cost savings, and digital transformation, brings a proven track record of operational efficiency and capital allocation expertise. Her background in leading complex global finance organizations and her roles on the audit committees of Mars and UPS suggest she will strengthen financial controls, optimize working capital, and accelerate initiatives that enhance margin stability—particularly valuable as the company navigates IRA-driven price reductions and GLP-1 growth normalization. This leadership transition is a quiet but significant catalyst for sustained financial performance that is not yet priced into the stock.

▼ Bear case

Cencora’s U.S. Healthcare Solutions revenue growth is being structurally undermined by the accelerating shift of branded drugs to biosimilars and generics in the Part D mail-order channel, where the company explicitly acknowledged that the speed of brand conversions at its large mail-order pharmacy customer was faster than anticipated and is not expected to normalize. This trend is not merely transitory—it reflects a fundamental change in payer and PBM behavior that reduces the company’s role in the supply chain for lower-margin products, directly pressuring revenue growth and forcing a permanent downgrade of its full-year revenue guidance from 7%–9% to 4%–6%, with no indication of recovery in the long-term outlook.
While Cencora highlights the benefit of biosimilars in the Part B space (physician-administered drugs), it avoids addressing the growing risk that biosimilars are increasingly being distributed through health system-owned specialty pharmacies or integrated delivery networks, bypassing traditional wholesalers like Cencora entirely. As health systems vertically integrate and seek greater control over high-cost specialty drug procurement—especially for oncology and immunology therapies—Cencora’s GPO distribution and MSO platforms may face declining relevance, threatening the very specialty growth narrative it relies on for future operating income expansion.
The company’s reliance on MSOs as a growth engine is increasingly exposed to concentration risk, with OneOncology and RCA representing a significant portion of its specialty platform. Despite claims of synergies, the integration is still in early days, and there is no disclosed timeline for when these synergies will meaningfully impact operating income. Furthermore, the MSO business model is inherently vulnerable to shifts in physician employment trends—if more practices join large health systems or opt for employed models, the value proposition of independent MSOs could erode, undermining a core pillar of Cencora’s long-term growth strategy.
Cencora’s operating income growth is being flattered by non-recurring and non-operating items, most notably the $1.1 billion gain on the remeasurement of its OneOncology equity investment, which is excluded from adjusted EPS but significantly inflates GAAP net income and creates a misleading impression of profitability. The company’s adjusted operating income growth of 6% in Q2 FY26 was driven more by the inclusion of OneOncology (which contributed less than the headwind from the lost oncology customer) and the suspension of depreciation on MWI (held for sale) than by organic core business performance, raising questions about the sustainability of its upgraded 12%–14% full-year operating income growth guidance without continued M&A or accounting tailwinds.
The appointment of Eva Boratto as CFO, while impressive on paper, introduces execution risk given her lack of direct experience in the pharmaceutical distribution sector. Her background at CVS Health (where she oversaw the Aetna integration) and Bath & Body Works—a retail apparel company—does not translate directly to the complex, low-margin, highly regulated world of pharmaceutical wholesaling, where success depends on deep expertise in manufacturer contracts, inventory turnover, and temperature-controlled logistics. This transition could lead to misaligned priorities or delayed decision-making in a sector where operational nuance is critical, especially as the company navigates impending GLP-1 pricing changes in 2027 and intensifying competition from rivals like AmerisourceBergen (now part of Cencora’s legacy) and McKesson.

Cencora’s U.S. Healthcare Solutions revenue growth is being structurally undermined by the accelerating shift of branded drugs to biosimilars and generics in the Part D mail-order channel, where the company explicitly acknowledged that the speed of brand conversions at its large mail-order pharmacy customer was faster than anticipated and is not expected to normalize. This trend is not merely transitory—it reflects a fundamental change in payer and PBM behavior that reduces the company’s role in the supply chain for lower-margin products, directly pressuring revenue growth and forcing a permanent downgrade of its full-year revenue guidance from 7%–9% to 4%–6%, with no indication of recovery in the long-term outlook.
While Cencora highlights the benefit of biosimilars in the Part B space (physician-administered drugs), it avoids addressing the growing risk that biosimilars are increasingly being distributed through health system-owned specialty pharmacies or integrated delivery networks, bypassing traditional wholesalers like Cencora entirely. As health systems vertically integrate and seek greater control over high-cost specialty drug procurement—especially for oncology and immunology therapies—Cencora’s GPO distribution and MSO platforms may face declining relevance, threatening the very specialty growth narrative it relies on for future operating income expansion.
The company’s reliance on MSOs as a growth engine is increasingly exposed to concentration risk, with OneOncology and RCA representing a significant portion of its specialty platform. Despite claims of synergies, the integration is still in early days, and there is no disclosed timeline for when these synergies will meaningfully impact operating income. Furthermore, the MSO business model is inherently vulnerable to shifts in physician employment trends—if more practices join large health systems or opt for employed models, the value proposition of independent MSOs could erode, undermining a core pillar of Cencora’s long-term growth strategy.
Cencora’s operating income growth is being flattered by non-recurring and non-operating items, most notably the $1.1 billion gain on the remeasurement of its OneOncology equity investment, which is excluded from adjusted EPS but significantly inflates GAAP net income and creates a misleading impression of profitability. The company’s adjusted operating income growth of 6% in Q2 FY26 was driven more by the inclusion of OneOncology (which contributed less than the headwind from the lost oncology customer) and the suspension of depreciation on MWI (held for sale) than by organic core business performance, raising questions about the sustainability of its upgraded 12%–14% full-year operating income growth guidance without continued M&A or accounting tailwinds.
The appointment of Eva Boratto as CFO, while impressive on paper, introduces execution risk given her lack of direct experience in the pharmaceutical distribution sector. Her background at CVS Health (where she oversaw the Aetna integration) and Bath & Body Works—a retail apparel company—does not translate directly to the complex, low-margin, highly regulated world of pharmaceutical wholesaling, where success depends on deep expertise in manufacturer contracts, inventory turnover, and temperature-controlled logistics. This transition could lead to misaligned priorities or delayed decision-making in a sector where operational nuance is critical, especially as the company navigates impending GLP-1 pricing changes in 2027 and intensifying competition from rivals like AmerisourceBergen (now part of Cencora’s legacy) and McKesson.

Segments Breakdown of Revenue (2025)

Peer Comparison

Companies in the Medical Distribution

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	MCK	Mckesson Corp	105.70 Bn	20.73	0.26	6.56 Bn
2	COR	Cencora, Inc.	60.83 Bn	23.83	0.19	12.39 Bn
3	CAH	Cardinal Health Inc	54.12 Bn	34.96	0.22	8.92 Bn
4	HSIC	Henry Schein Inc	9.86 Bn	24.10	0.74	3.37 Bn
5	AHG	Akso Health Group	3.12 Bn	-	-	0.00 Bn
6	YI	111, Inc.	0.66 Bn	-71.09	0.38	0.03 Bn
7	ACH	Accendra Health Inc/Va/	0.25 Bn	-0.26	0.09	2.10 Bn
8	FOCL	Edap Tms Sa	0.23 Bn	-7.32	3.08	0.02 Bn

Research Tools

Developers

About

Investment Thesis

Segments Breakdown of Revenue (2025)

Segments Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Segments Breakdown of Revenue (2025)

Segments Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password